Introduction {#sec1}
============

Breast cancer is the most common cause of death in women in developed countries. The increase in the number of newly diagnosed cases of the disease is accompanied by a decreased mortality rate. This trend is observed particularly in countries of Western Europe and the United States of America \[[@cit0001]\].

The prognostic data describing the epidemiological situation in Poland show that at the end of the current decade the number of new breast cancer cases may exceed 20,000 a year \[[@cit0001], [@cit0002]\]. According to information from the National Cancer Registry in Poland there is little increase in the five-year relative survival rate: from 75% in 2000--2002 to 77.2% in 2003--2005 \[[@cit0003]\].

Alongside the gradually increasing number of newly diagnosed breast cancer cases in Poland, the overall rate of early-stage breast cancer has also increased. This phenomenon resulted from an organised, population-based mammography screening program \[[@cit0004]\]. Diagnosing breast cancer quickly and accurately is vital because the earlier it is detected, the greater the chances of implementing conserving procedures -- sentinel lymph node biopsy (SLNB) and breast conserving therapy (BCT) \[[@cit0003], [@cit0004]\].

Properly planned and performed diagnostic tests allow reliable determination of the clinical stage of cancer. They also make it possible to choose the right treatment strategy for the patient. According to the current clinical standards, the necessary tasks regarding therapeutic management of breast cancer patients also include the retrospective audits related to the overall treatment outcomes \[[@cit0005], [@cit0006]\]. This also applies to determining the type of operating procedure needed, which is particularly important for patients with breast cancer. As demonstrated by Gruber *et al.*, properly performed preoperative diagnostics reduces the incidence of non-therapeutic axillary lymphadenectomy by 40% \[[@cit0007]\].

Among currently used diagnostic methods for axillary lymph nodes verification in patients with invasive breast cancer, ultrasonography (USS) is the most accessible and affordable. It is also characterised by reproducibility and possibility of high objectification of obtained results \[[@cit0008]\]. The sensitivity and specificity of this test in assessing the presence of metastatic lesions in regional lymph nodes is 53--96% and 50--75%, respectively \[[@cit0009]--[@cit0012]\].

In addition to the above-mentioned advantages, USS scans make it possible to increase the sensitivity of screening for early detection of breast cancer, routinely performed mammography \[[@cit0013]\]. This is especially noticeable in patients with significant breast density, including the presence of suspicious microcalcifications \[[@cit0013]--[@cit0015]\]. Postoperative ultrasonography surveillance is feasible in breast cancer patients, especially following conserving procedures (SLNB, BCT) \[[@cit0013], [@cit0016]\].

In this study, we evaluated the clinical value of preoperative USS performed during initial staging of the disease in patients with early-stage breast cancer. The analysis focused mainly on the possibility of USS examination for accurate verification of axillary lymph nodes.

Material and methods {#sec2}
====================

The study was conducted in the form of a prospective analysis. The evaluation included patients with locally advanced breast cancer, who were referred for the sentinel node biopsy procedure. Patients were hospitalised in the period from March 2012 to May 2013, in the highest reference centre for surgical treatment of malignant neoplasms of the breast.

Patients enrolled to the trial did not have suspected axillary lymph nodes (patients with N0 score of clinical staging) in physical examination and USS at cancer diagnosis. Another criterion was a period of eight weeks prior to the surgery, during which initial USS examination was performed.

One day prior to the procedure, an additional assessment of the axillary lymph nodes was performed in each patient. All tests were conducted by the same radiologist. Regardless of the possible findings in the study of abnormalities within the armpit, each patient underwent a sentinel node biopsy ([Fig. 1](#f0001){ref-type="fig"}).
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After assessing the results of the pathological report, the usefulness of preoperative ultrasonography for the detection of metastatic lesions present in SLNB-removed lymph nodes was verified. The sensitivity and specificity of the test and the predictive value of the positive and negative test results were determined for this purpose. Definitions: test sensitivity -- the quotient of the results of the truly positive test and the sum of the results of the truly positive and the false negative: TP/TP + FN (true positive, false negative), test specificity -- the quotient of the results truly negative and the sum of the results truly negative and false positive: TN/TN + FP (true negative, false positive), positive predictive value (PPV) -- the quotient of the results of the truly positive test and the sum of the results truly positive and false positive (TP/TP + FP), and negative predictive value (NPV) -- the quotient of the results truly negative and the sum of the results truly negative and false negative (TN/TN + FN).

An attempt was also made to define factors that may affect the onset of abnormal preoperative ultrasonography (false-positive and false-negative results). The analysis included the clinical data of patients (age, BMI) and clinical features of breast cancer (tumour size -- clinical and pathological findings, palpation of lesions, histological grade, histological type and cancer type, oestrogen, progesterone, and HER2 receptor status, and Ki-67 mitotic factor value). For statistical calculations, a linear regression model was used. The occurrence of a statistically significant difference between the compared groups of data was recognised at the values of significance level *p* \< 0.05.

Results {#sec3}
=======

The analysis comprised 172 patients aged 59.6 ±10.2 years (range 32 to 81 years).

In nearly 85% of patients, preoperative assessment of axillary lymph nodes showed no suspicious lesions. 26 patients (15.1%) were diagnosed with questionable lymph nodes ([Fig. 2](#f0002){ref-type="fig"}).

![Results of preoperative USS examination of axillary lymph nodes and pathological assessment of sentinel nodes removed during SLNB](WO-22-82644-g002){#f0002}

As a result of the pathological assessment of lymph nodes removed during SLNB, 32 patients (18.6%) were diagnosed with metastatic lesions. In the case of 14.4% of patients (21/146) with correct axillary ultrasonography (USS -- N0 patients), prognostic testing was not confirmed (histopathological result -- pN1, patients with false positive USS scan). In 42.3% of patients (11/26) presenting suspected lymph nodes in USS examination -- N1 patients -- histopathological findings from SLNB revealed metastatic lesions (with a truly positive result of USS, [Fig. 2](#f0002){ref-type="fig"}). The sensitivity of preoperative ultrasonography scan was 89.3%, specificity 34.4%, PPV -- 85.6%, and NPV -- 42.3%.

Based on the performed calculations, none of the clinical factors tested showed a statistically significant effect on the possibility of abnormal ultrasonography result. A detailed summary of the clinical data of patients with normal (positive and negative) and abnormal (false positive and false negative) results from the preoperative evaluation of axillary lymph nodes is presented in [Table 1](#t0001){ref-type="table"}.

###### 

Study patients -- clinical and pathological features

  Clinical and pathological features        Correct result of preoperative USS (TN + TP) *n* = 136   Incorrect result of preoperative USS (FN + FP) *n* = 36   *p*           
  ----------------------------------------- -------------------------------------------------------- --------------------------------------------------------- ----- ------- --------
  Age                                                                                                                                                                        
   \< 40 years                              9                                                        6.6                                                       2     5.6     0.896
   40 to 60 years                           63                                                       46.3                                                      13    36.1    0.765
   \> 60 years                              64                                                       47.1                                                      21    58.3    0.657
  BMI                                                                                                                                                                        
   Normal (18.5--24.9)                      47                                                       34.6                                                      12    33.3    0.876
   Overweight (25--29.9)                    52                                                       38.2                                                      13    36.1    0.764
   Obesity (≥ 30)                           37                                                       27.2                                                      11    30.6    0.795
  Palpable tumour                           79                                                       58.1                                                      24    66.7    0.205
  Tumour size (in USS scan)                                                                                                                                                  
   T1a                                      14                                                       10.7                                                      --    -19.4   -0.322
   T1b                                      37                                                       28.2                                                      7     58.3    0.687
   T1c                                      66                                                       50.4                                                      21    22.2    0.778
   T2                                       14                                                       10.7                                                      8     --      --
   T3                                       --                                                       --                                                        --    --      --
   No data                                  5                                                        --                                                        --             
  Tumour size (pathological report -- pT)                                                                                                                                    
   T0 (after BMU)                           2                                                        1.5                                                       --    --      --
   T1mic                                    4                                                        3                                                         1     2.8     0.288
   T1a                                      3                                                        2.2                                                       --    --      --
   T1b                                      23                                                       17                                                        3     8.3     0.657
   T1c                                      77                                                       57                                                        19    52.8    0.864
   T2                                       26                                                       19.3                                                      13    36.1    0.764
   T3                                       --                                                       --                                                        --    --      --
   T4                                       1                                                        0.6                                                       --    --      --
  Histological grading                                                                                                                                                       
   G1                                       12                                                       9.2                                                       3     8.6     0.674
   G2                                       95                                                       72.5                                                      24    68.6    0.453
   G3                                       24                                                       18.3                                                      8     22.9    0.452
   no data                                  5                                                        --                                                        1     --      --
  Histological type                                                                                                                                                          
   ductal carcinoma                         115                                                      84.6                                                      32    88.9    0.673
   lobular carcinoma                        18                                                       13.2                                                      3     8.3     0.564
   another invasive type                    3                                                        2.2                                                       1     2.8     0.765
  ER positive                               116                                                      85.3                                                      28    77.8    0.345
  ER negative                               20                                                       14.7                                                      8     22.2    0.632
  PR positive                               116                                                      85.3                                                      28    77.8    0.433
  PR negative                               20                                                       14.7                                                      8     22.2    0.245
  HER2 positive                             19                                                       14                                                        2     5.6     0.236
  HER2 negative                             117                                                      86                                                        34    94.4    0.435
  Ki-67 index                                                                                                                                                                
   0--14%                                   37                                                       38.1                                                      17    60.7    0.534
   15--30%                                  49                                                       50.5                                                      6     21.4    0.653
   31--45%                                  4                                                        4.1                                                       4     14.3    0.247
   above 45%                                7                                                        7.2                                                       1     3.6     0.543
   no data                                  39                                                       --                                                        8     --      --
  Biological type                                                                                                                                                            
   luminal A                                37                                                       30.3                                                      17    50      0.534
   luminal B HER2 negative                  56                                                       45.9                                                      8     23.5    0.653
   luminal B HER2 positive                  10                                                       8.2                                                       1     2.9     0.435
   HER2 positive                            9                                                        7.4                                                       1     2.9     0.678
   triple negative                          10                                                       8.2                                                       7     20.6    0.634
   no data                                  14                                                       --                                                        2     --      --
  All                                       136                                                      100                                                       36    100      

TN -- negative result; TP -- positive result; FN -- false negative result; FP -- false positive result; n -- number of patients; p -- significance level; BMI -- body mass index; BMU -- Mammotome biopsy; ER -- oestrogen receptor; PR -- progesterone receptor; HER2 -- HER2 receptor

Discussion {#sec4}
==========

Consistent with the trial's aim, selective assessment of the diagnostic value of ultrasonography in breast cancer patients qualified to procedures conserving lymph nodes of the axillary fossa was conducted. Unlike most clinical trials, verified imaging studies were performed directly prior to surgical procedure, regardless of former preoperative diagnostics. In this way, the possibility of influencing the result of the length of time between the time of performing the test and performing the surgery is omitted. It brings new perspectives to preoperative diagnostics of patients submitted for SLNB procedure.

According to our previous analyses, the lowest rates of metastasis in sentinel lymph nodes can be found in patients who have undergone a USS scan (with correct results) directly prior to SLNB procedure. This concerns the sensitivity as well as the specificity of the study being evaluated \[[@cit0016]\].

We also resigned from the additional methods for verifying axillary lymph nodes, as shown by some of the ultrasound examinations we reviewed. According to the accepted research criteria, a prospective analysis focused on the selective evaluation of the clinical value of USS testing. Therefore, in spite of the preoperative axillary lymph node abnormalities, each patient underwent sentinel node biopsy. This proceeding was consistent with initial qualification for SLNB and corresponded with the standards for the diagnosis and treatment of early-stage breast cancer (SLNB was performed in patients with cN0 -- clinical assessment of axillary lymph node status).

Ultrasound was performed by one radiologist using the same ultrasound device, in order to achieve objective results.

Therefore, the principles adopted in our study may not correspond to the standard preparation for surgical procedure of patients with early-stage breast cancer. However, they make it possible to significantly reduce the impact on the results of other factors, apart from the factors selected for evaluation in a planned way.

According to Pinheiro *et al.*, axillary USS scan should be an integral part of routine diagnostic practice in patients with breast cancer. This is especially important for patients with primary tumours greater than 1 cm, because patients in this group benefit most from such procedures \[[@cit0017]\].

An analysis of the clinical value of preoperative USS scan was performed by Perhavec *et al.* The study included 470 breast cancer patients enrolled to the sentinel node biopsy procedure. The rate of metastatic lesions found after the SLNB was 43%. For patients diagnosed with preoperative ultrasonography, the percentage was lower -- 39% (101/257), and in patients in whom only physical examination was performed before SLNB -- 47% (101/213; *p* = 0.092). Patients in the USS group had a lower proportion of macrometastases in the removed sentinel lymph nodes (44% vs. 66%; *p* = 0.002). These changes were also smaller in size (5.4 vs. 6.8 mm; *p* = 0.027). According to the authors of the cited article, a higher diagnostic value in determining the preoperative status of the axillary lymph nodes is verified by ultrasonography (false-negative results in 39% of patients). On the other hand, the limitation of the preoperative assessment of axillary lymph node status for physical examination resulted in the presence of metastatic lesions in 47% of patients in a histopathological report of sentinel lymph nodes \[[@cit0018]\].

In a Johnson *et al.* study of 155 patients with normal preoperative ultrasonography, 29% had a positive histopathological examination after lymphadenectomy. In the group of patients with negative lymph node ultrasonography, tumour size was significantly lower (21 vs. 30 mm; *p* \< 0.02). In patients with false positive USS scan there were more cases of invasive lobular cancer (5% vs. 13%; *p* \< 0.001) and more cases of lymph vessel invasion (5% vs. 31%; *p* \< 0.001) \[[@cit0019]\]. In contrast to the cited study, there were no statistically significant differences in the patients we analysed for any of the clinical and pathological data included in the calculation.

In the Diepstraten *et al.* study of 9212 patients, it was demonstrated that up to 25% of correct USS results performed prior to SLNB were false negative. According to the authors, the clinical value of preoperative USS scan can be augmented by fine-needle aspiration biopsy (FNAB) of lymph nodes in carefully selected patients. It has been shown that the combination of both diagnostic methods enables detection of metastases in axillary lymph nodes in 50% of patients with false-negative lymph nodes evaluated in the USS test \[[@cit0020]\]. In Baruah *et al.*'s study preoperative USS scan combined with the aspiration biopsy of suspected lymph nodes allowed the avoidance of unnecessary SLNB in 28.5% of patients (in the group of patients with cancer cells as a result of biopsy, qualified for axillary lymphadenectomy with positive results of histological examination) \[[@cit0021]\].

An attempt was made to compare the treatment outcomes of patients with invasive breast cancer, who were enrolled in the sentinel node biopsy or treated without axillary lymph node verification in the European Institute of Oncology in Milan, in the ongoing SOUND (sentinel node vs. observation after axillary ultrasound) study. Clinical trial patient inclusion criteria are either the correct outcome of preoperative axillary lymph node USS scan, or the presence of a single positive lymph node verified in preoperative FNAB. The expected outcome of the study is the lack of statistically significant differences in the long-term follow-up in both groups of patients, which may allow a change in the standard of care for patients with early-stage breast cancer \[[@cit0022]\].

The sensitivity of preoperative ultrasonography in detecting metastatic lesions in sentinel nodes in the study group was 89.3%. This is comparable to the results acquired by Ciatto *et al.* (53--96%) and other authors \[[@cit0009]--[@cit0012]\]. In Koehler *et al.*, Genty *et al.*, and Garcia-Ortega *et al.*, the specificity of USS assessment was 50--75% \[[@cit0009], [@cit0011], [@cit0012]\]. Combined use of ultrasound with a FNAB is a useful complementary tool improving specificity of the verification to 100% \[[@cit0010]\]. The value we received at 34.4% is therefore lower than in the studies mentioned above.

Conclusions {#sec5}
===========

As shown in the analysis, it is possible to select patients who are not expected to have metastatic lesions in the lymph nodes removed during the SLNB procedure. This is possible by performing a preoperative USS assessment of axillary lymph nodes in patients with breast cancer, who are referred for treatment conserving lymph nodes of the armpit. Such early diagnostics is a safe and effective way of verifying the nodal status of the axilla.

The ultrasound examination is characterised by high sensitivity and high predictive value of the positive test result. As demonstrated, none of the analysed clinical features contributed to obtaining inaccurate preoperative ultrasound results. It should also be emphasised that technical limitations of the USS examination create restrictions for the study itself because the risk of receiving a non-conforming result (FN, FP results) can arise.
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